The AAV (Adeno-Associated Virus) vector market is a segment within the broader field of genomics focused on the development and commercialization of gene delivery tools based on the AAV. AAV vectors are widely used in gene therapy due to their ability to introduce therapeutic genes into various types of cells with high efficiency and their relatively low risk profile. These vectors are small, non-enveloped viruses that can infect both dividing and non-dividing cells and are deemed non-pathogenic, making them particularly suitable for delivering genetic payloads for therapeutic purposes. The market for AAV vectors has expanded with the rising prevalence of genetic disorders, advances in genetic research, and the increasing number of gene therapy candidates entering clinical trials. There is a growing interest in utilizing AAV vectors for the treatment of a wide array of diseases, including monogenic disorders as well as more complex conditions. Several companies have risen to prominence within the AAV vector market. Notables include Spark Therapeutics, renowned for pioneering gene therapies; BioMarin Pharmaceutical, which delves into therapies for rare genetic diseases; UniQure, recognized for its work in hemophilia gene therapy; and Regenxbio, which focuses on proprietary AAV vector technologies. These companies, along with others such as Voyager Therapeutics and bluebird bio, are instrumental in the exploration and commercialization of AAV vector-based gene therapies. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
